aTyr Pharma (ATYR) Competitors

aTyr Pharma (NASDAQ:ATYR) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

Which has more volatility and risk, ATYR or IMCR?

aTyr Pharma has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Is ATYR or IMCR more profitable?

aTyr Pharma has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-93.69%	-68.83%
Immunocore	-5.70%	-5.40%	-1.93%

Do analysts rate ATYR or IMCR?

aTyr Pharma presently has a consensus price target of $21.25, indicating a potential upside of 333.67%. Immunocore has a consensus price target of $58.00, indicating a potential upside of 76.40%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe aTyr Pharma is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Immunocore	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has higher earnings and valuation, ATYR or IMCR?

Immunocore has higher revenue and earnings than aTyr Pharma. Immunocore is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$230K	2,087.61	-$64.02M	-$0.80	-6.13
Immunocore	$310.20M	5.32	-$51.09M	-$0.40	-82.20

Does the media favor ATYR or IMCR?

In the previous week, Immunocore had 2 more articles in the media than aTyr Pharma. MarketBeat recorded 14 mentions for Immunocore and 12 mentions for aTyr Pharma. Immunocore's average media sentiment score of 0.94 beat aTyr Pharma's score of 0.22 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of ATYR or IMCR?

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Immunocore beats aTyr Pharma on 10 of the 17 factors compared between the two stocks.